Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 14/20 | 0.50 |
| ▸ | NUDT1 | P36639 | 2/20 | 0.50 |
| ▸ | ADORA1 | P30542 | 14/20 | 0.49 |
| ▸ | XDH | P47989 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.44 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.43 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10567530 | 0.78 | ADORA2A (0.53) | ADORA2ANUDT1ADORA1XDHALDH1A1 | |
| SCHEMBL29541280 | 0.78 | ADORA2A (0.53) | ADORA2ANUDT1ADORA1XDHALDH1A1 | |
| Bropirimine SCHEMBL4321472 | 0.78 | ADORA2A (0.50) | ADORA2ANUDT1ADORA1XDHADORA2B | |
| SCHEMBL6817514 | 0.78 | ADORA2A (0.50) | ADORA2ANUDT1ADORA1ALDH1A1CYP1A2 | |
| SCHEMBL822872 | 0.75 | NUDT1 (0.56) | NUDT1XDHALDH1A1CYP1A2HPGD | |
| SCHEMBL2755511 | 0.75 | KDM4E (0.40) | ADORA2AADORA1XDHALDH1A1HPGD | |
| SCHEMBL21731039 | 0.75 | ADORA2A (0.47) | ADORA2ANUDT1ADORA1XDHALDH1A1 | |
| SCHEMBL29502741 | 0.75 | ADORA2A (0.47) | ADORA2ANUDT1ADORA1XDHALDH1A1 | |
| SCHEMBL9289229 | 0.74 | ALDH1A1 (0.55) | ADORA2ANUDT1ADORA1ALDH1A1CYP1A2 | |
| SCHEMBL24310426 | 0.74 | ADORA2A (0.64) | ADORA2ANUDT1ADORA1XDHALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8211863-B2 | Administration of TLR7 ligands and prodrugs thereof for treatment of infection by hepatitis C virus | ANADYS PHARMACEUTICALS, INC. (US) | 2012-07-03 | — | — | US | disclosed |
| US-20120028999-A1 | ADMINISTRATION OF TLR7 LIGANDS AND PRODRUGS THEREOF FOR TREATMENT OF INFECTION BY HEPATITIS C VIRUS | ANADYS PHARMACEUTICALS, INC. (US) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028999-A1 | ADMINISTRATION OF TLR7 LIGANDS AND PRODRUGS THEREOF FOR TREATMENT OF INFECTION BY HEPATITIS C VIRUS | TLR7, TLR3, TLR9 | ADORA2A 166/4885NUDT1 150/4885ADORA1 287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.